In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

P&G and Hoechst commercialize P&G's Actonel bone therapy

Executive Summary

Through a collaboration that the partners are calling the "Alliance for Better Bone Health," P&G and Hoechst Marion have agreed to commercialize and jointly market P&G's Actonel for osteoporosis/bone disease in all areas outside Japan. If approved for osteoporosis, Actonel will compete with Merck's Fosamax (alendronate).
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies